About Candel Therapeutics
Candel Therapeutics is a company based in United States founded in 1999. Candel Therapeutics has raised $110.3 million across 14 funding rounds from investors including HHS, Sands Capital Ventures and Northpond Ventures. The company has 38 employees as of December 31, 2024. Candel Therapeutics offers products and services including CAN-2409 and CAN-3110. Candel Therapeutics operates in a competitive market with competitors including Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen, among others.
- Headquarter United States
- Employees 38 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Candel Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$55.18 M (USD)-45.44as on Dec 31, 2024
-
EBITDA
-$32.38 M (USD)12.93as on Dec 31, 2024
-
Total Equity Funding
$110.3 M (USD)
in 14 rounds
-
Latest Funding Round
$22.5 M (USD), Series C
Apr 01, 2019
-
Investors
HHS
& 5 more
-
Employee Count
38
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Candel Therapeutics
Candel Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CADL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Candel Therapeutics
Candel Therapeutics offers a comprehensive portfolio of products and services, including CAN-2409 and CAN-3110.
Mechanism of action for targeted cancer treatment using viral agents.
Another viral mechanism designed for cancer immunotherapy applications.
People of Candel Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
19 people
Scientific Team
8 people
Clinical Team
6 people
Research Team
5 people
Data Analysis and Operations Team
4 people
Software Development Team
3 people
Senior Team
3 people
Human Resources and Administration
2 people
Unlock access to complete
Funding Insights of Candel Therapeutics
Candel Therapeutics has successfully raised a total of $110.3M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $22.5 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Candel Therapeutics
Candel Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Sands Capital Ventures and Northpond Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Candel Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Candel Therapeutics
Investment portfolio details for Candel Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Candel Therapeutics
Detailed financials for Candel Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Candel Therapeutics Comparisons
Peer comparison for Candel Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Candel Therapeutics
Candel Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Replimune, TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and GigaGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of oncolytic immunotherapies
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
Detailed competitors of Candel Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Candel Therapeutics
Complete news archive for Candel Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Candel Therapeutics
Candel Therapeutics was founded in 1999 and raised its 1st funding round 5 years after it was founded.
Candel Therapeutics is headquartered in United States.
Aguilar Estuardo is the current CEO of Candel Therapeutics.
Candel Therapeutics is a funded company, having raised a total of $110.3M across 14 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Candel Therapeutics is 38.
Candel Therapeutics was founded in 1999 in the United States. Focus is placed on the biotechnology sector, where viral immunotherapies are created to target cancer. These therapies work by lysing tumor cells to release antigens and neoantigens, which trigger in situ vaccination and activate both innate and adaptive immune responses. Operations center on research and development of such immunotherapies, with leadership provided by CEO Aguilar Estuardo.
Candel Therapeutics's top competitors include Hummingbird Bioscience, Replimune and Lyell Immunopharma.
Candel Therapeutics offers CAN-2409 and CAN-3110.
Yes, Candel Therapeutics is publicly traded on NASDAQ under the ticker symbol CADL.
Candel Therapeutics has 6 investors. Key investors include HHS, Sands Capital Ventures, Northpond Ventures, PBM Capital, and National Securities Corporation.
The ticker symbol of Candel Therapeutics is CADL on NASDAQ.